Clinical trials: Cancer, Bladder
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
This phase II trial studies the side effects and how well radiation therapy and durvalumab with or without tremelimumab work in treating participants with bladder cancer that cannot be removed by surgery, has spread to nearby…
- Conditions
- Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
- Trial name
- NCT03601455
- Testing
- Durvalumab, External Beam Radiation Therapy, Tremelimumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Urinary Bladder Cancer
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) between diagnosis and radical cystectomy (RC).
- Trial name
- NCT02722538
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 23 people
- Sponsor
- Taris Biomedical LLC
Neoplasms, Malignancies
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib, in solid tumors when given over a different period of time than normally used.
- Trial name
- NCT02257476
- Testing
- Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Bladder Cancer
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
In the treatment of localized/locally advanced urothelial cancer, there are several questions that have not yet been resolved, such as the limited benefit of cisplatin-based chemotherapy in the adjuvant or neoadjuvant context…
- Trial name
- DUTRENEO (NCT03472274)
- Testing
- Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy
- Where
- 11 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Bladder Cancer
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor…
- Trial name
- NCT06153849
- Testing
- urine sample collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Urothelial Cancer, Bladder Cancer
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
This study will involve subjects who have advanced urothelial cancer who are platinum refractory (platinum based chemotherapies that are not effective in treating the cancer), and who are over-expressing EGFR and/or HER2, or do…
- Trial name
- NCT01700010
- Testing
- Lapatinib and Paclitaxel
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, URINARY BLADDER
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients.
- Trial name
- NCT00714948
- Testing
- gemcitabine and cisplatin plus sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Muscle-invasive Bladder Cancer
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients…
- Trial name
- NCT06373055
- Testing
- neoadjuvant chemotherapy followed by radical cystectomy
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Yonsei University
Bladder Cancer, Urinary Bladder
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder…
- Trial name
- NCT00847015
- Testing
- Sunitinib, Gemcitabine, cisplatin
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder (Urothelial, Transitional Cell) Cancer, TURBT
INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP
Transurethral resection of bladder tumor (TURBT) is the cornerstone procedure in the diagnosis and treatment of bladder cancer but is associated with a spectrum of intraoperative bladder injuries ranging from minor mucosal tears…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, TURBT, Bladder Injury
- Trial name
- BICEP in TURBT (NCT07396038)
- Testing
- No intervention is assigned as part of this observational study. All procedures are performed as part of routine clinical care.
- Volunteers
- 1,000 people
- Sponsor
- Necmettin Erbakan University
Bladder Cancer
Safety Study on AdCD40L Gene Therapy for Bladder Cancer
The study objective is to evaluate the feasibility of three instillations of immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer.
- Trial name
- NCT00891748
- Testing
- AdCD40L
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Uppsala University
Muscle-Invasive Bladder Carcinoma, Tumor
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO)…
- Trial name
- NCT06417190
- Testing
- Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Leslie Ballas
Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
- Trial name
- NCT01915121
- Testing
- Education Intervention, Nutrition Intervention
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cystoscopic Surgical Procedures, Pain
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia
Cystoscopy with local anesthesia is commonly performed for the follow-up of bladder cancer, evaluation of hematuria, assessment of urethral strictures, and examination of the lower urinary tract.
- Trial name
- NCT06944314
- Testing
- Diagnostic procedures, Flexible Cystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Marmara University
Bladder Cancer
Gender Related Coping and Survivorship for Genitourinary Cancers
This research is being done to learn more about coping and survivorship of women with bladder cancer, specifically regarding psychosocial distress and sexual dysfunction.
- Trial name
- NCT05649306
- Testing
- Additional Education, Questionnaires, Attendance Diary
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Johns Hopkins University
Microscopic or Gross Hematuria
Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer
The purpose of the study is to evaluate subjects with gross or microscopic hematuria undergoing scheduled cystoscopy to determine the absence or presence of bladder cancer.
- Trial name
- NCT00975455
- Where
- 13 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Predictive Biosciences
Prostatic Neoplasm, Urinary Bladder Neoplasm
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
In urologic robotic surgery with steep Trendelenburg position, maintenance of cardiac preload and cardiac output is important for clinical prognosis.
- Trial name
- NCT02977143
- Testing
- Fluid loading of volulyte 300 ml
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Transitional Cell Carcinoma of Urinary Bladder
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
The purpose of this study is to define the optimal management of localised transitional cell carcinoma (TCC) of the urinary bladder. The main objective is to evaluate whether chemoradiation is superior to radiotherapy alone.
- Trial name
- NCT00330499
- Testing
- Cisplatin, External beam radiation treatment
- Where
- 22 sites in Australia, New Zealand
- Volunteers
- 67 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Carcinoma in Situ, Non Muscle Invasive Bladder Cancer
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.
- Trial name
- NCT01731652
- Testing
- TMX-101
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Telormedix SA
Non-muscle Invasive Bladder Cancer
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive bladder cancer.
- Trial name
- NCT01458847
- Testing
- cis-UCA solution
- Where
- 2 sites in Finland
- Volunteers
- 12 people
- Sponsor
- BioCis Pharma Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.